Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens
Links shared publicly online about this topic.
- 1,177total visits
Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, is pleased to announce it has signed a worldwide non-exclusive licensing agreement with the National Institutes of Health ('NIH'), a division of the U.S. Department of Health and Human Services, for use of the melanoma antigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine for melanoma, SCIB1.
View full resource at news-medical.net
Tags: Vaccination, Cancer, Skin Cancer, Melanoma, Health and Human Services, National Institutes of Health, Vaccine
Most Recently Shared on May 11, 2010 at 10:03 am By:
Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens: Scancell Holdings Plc... http://bit.ly/bVyCPh
Advertisement
